Pfizer Inc. (NYSE:PFE) is beginning to show signs of steadier growth following the sharp decline in its pandemic-related business. The pharmaceutical giant reported a 1% year-over-year operational increase in fiscal Q2 2026 revenue to $15.0 billion, while revenue excluding Comirnaty and Paxlovid grew 5% operationally. Management also raised the midpoint of its full-year revenue guidance.
However, Pfizer’s (NYSE:PFE) recovery still faces a major test: whether growth from newer products and cost reductions can compensate for upcoming patent expirations across several established medicines.
Bull Case
A point of optimism for investors is that Pfizer (NYSE:PFE) is becoming less dependent on unpredictable COVID-related sales, as its non-COVID product portfolio drove growth. Launched and acquired medicines generated $3.2 billion in quarterly revenue and grew 18% operationally. The company also cut its 2026 COVID-19 revenue estimate to approximately $4 billion, primarily due to weaker PAXLOVID demand.
Growth is also becoming more diversified for the company, with Padcev gaining market share in bladder cancer, and Vyndaqel continuing to benefit from increased diagnosis and international demand. Padcev revenue rose 23% operationally to $667 million, while the Vyndaqel family generated $1.76 billion, representing 8% operational growth. This is significant because the company needs several products to support its post-COVID recovery and not just one blockbuster.
Pfizer (NYSE:PFE) also expanded its cost-savings target and remains on track to produce approximately $5.7 billion in net savings by the end of 2026. It expects $6.7 billion in total net savings from its cost reductions through 2029 as it looks to offset declining COVID-related revenue and restore sustainable growth. These savings could support margins and free up resources for investment in oncology and obesity, even if revenue growth remains moderate.
Bear Case
Operationally, Pfizer’s (NYSE:PFE) revenue growth was only 1%, with foreign-exchange movements contributing to the reported increase. This holds significance because the company’s turnaround is not yet producing strong underlying growth extending throughout the company. Pfizer (NYSE:PFE) also reported a GAAP pre-tax loss from continuing operations, partly because of impairment, legal, restructuring, and acquisition-related charges. Therefore, reported profitability remains affected by restructuring and portfolio-related costs.
Another crucial point for investors is the company’s patent losses. Pfizer (NYSE:PFE) expects significant revenue pressure from patent expirations between 2026 and 2030, with the major products facing competition including Eliquis, Ibrance, and Xtandi. The company’s financial guidance for full-year 2026 shows an anticipated unfavorable revenue impact of approximately $1.1 billion due to recent and expected generic and biosimilar competition for certain products that have either recently lost patent or regulatory protection or are expected to lose patent or regulatory protection. While Padcev and Vyndaqel are growing, investors still lack definitive evidence that Pfizer’s (NYSE:PFE) newer portfolio can replace the combined revenue exposed to patent losses.
What Do Hedge Funds Say?
Hedge fund sentiment offers another perspective into Pfizer’s (NYSE:PFE) future outlook. According to Insider Monkey’s database of 1,022 hedge funds, hedge fund ownership for the stock rose modestly from 81 in Q4 2025 to 83 in Q1 2026. While the increase is too small to signal a decisive shift in institutional conviction, it indicates that hedge fund interest remained broadly stable with a slightly positive tilt as Pfizer (NYSE:PFE) continued its turnaround efforts.
Conclusion
Pfizer’s (NYSE:PFE) turnaround is becoming more credible as its non-COVID portfolio expands, products such as Padcev and Vyndaqel deliver growth, and management reduces the company’s cost base. However, the recovery remains incomplete. Operational revenue growth is still modest, and upcoming patent expirations could place substantial pressure on several established franchises. Pfizer’s (NYSE:PFE) lower cost structure provides breathing room, but the long-term investment case ultimately depends on whether its newer medicines can become large enough to replace the revenue it is preparing to lose.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center